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Statement of Translational Relevance: 
HSP90 is an ATP-dependent molecular chaperone that is critical to the folding and function of a 
wide range of client proteins involved in prostate cancer progression, including the androgen 
receptor (AR), HER-2, glucocorticoid receptor (GR), and AKT. Onalespib is a potent, fragment- 
derived HSP90 inhibitor with good tissue distribution and long tumor half-life in preclinical 
models leading to prolonged knockdown of HSP90 client proteins. Onalespib demonstrated anti-
tumor activity in preclinical models of CRPC, causing depletion of full-length AR and the AR 
splice variant AR-V7. This study represents the first clinical trial of an HSP90 inhibitor in 
combination with abiraterone acetate (AA) in patients with castration-resistant prostate cancer 
(CRPC) no longer responding to AA. The tolerability, pharmacokinetic, pharmacodynamic and 
anti-tumor activity of two dosing schedules of onalespib and abiraterone acetate were 
investigated. Pharmacodynamic effects and AR modulation by onalespib were evaluated in 
circulating tumor cells and paired pre- and post-tumor biopsies.  
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Abstract   
Purpose: Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with 
preclinical activity in castration-resistant prostate cancer (CPRC) models. This Phase 1/2 trial 
evaluated onalespib in combination with abiraterone acetate (AA) and either prednisone or 
prednisolone (P) in men with CRPC progressing on AA/P. 
Experimental Design:  Subjects with progressing CRPC were randomized to receive one of two 
regimens of onalespib combined with AA/P. Onalespib was administered as intravenous (IV) 
infusion starting at 220 mg/m2 once weekly for 3 of 4 weeks (Regimen 1); or at 120 mg/m2 on 
Day 1 and Day 2 weekly for 3 of 4 weeks (Regimen 2). Primary endpoints were response rate 
and safety. Secondary endpoints included evaluation of androgen receptor (AR) depletion in 
circulating tumor cells (CTCs) and in fresh tumor tissue biopsies.   
Results: Forty-eight patients were treated with onalespib in combination with AA/P. The most 
common ≥ Grade 3 toxicities related to onalespib included diarrhea (21%) and fatigue (13%). 
Diarrhea was dose-limiting at 260 mg/m2 and 160 mg/m2 for Regimen 1 and Regimen 2, 
respectively. Transient decreases in CTC counts and AR expression in CTC were observed in 
both regimens. HSP72 was significantly up-regulated following onalespib treatment, but only a 
modest decrease in AR and GR was shown in paired pre- and post-treatment tumor biopsy 
samples. No subjects showed an objective or PSA response. 
Conclusions: Onalespib in combination with AA/P, showed mild evidence of some biological 
effect, however this effect did not translate into clinical activity, hence further exploration of this 
combination was not justified.  
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INTRODUCTION 
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of 
cancer deaths in males worldwide(1). Androgen deprivation therapy (ADT) remains the mainstay 
of treatment for patients with advanced disease. However, in almost all patients, response to 
initial ADT is unfortunately followed by the emergence of resistance, so-called castration-
resistant prostate cancer (CRPC). The efficacy of abiraterone acetate (AA) (2) and enzalutamide 
(3) in patients progressing after multiple prior hormonal manipulations indicates that CRPC 
generally remains dependent on the androgen receptor (AR) signaling axis (4). However, 
resistance to second-generation hormonal treatment is now common and a major challenge in the 
management of prostate cancer.  
Resistance to enzalutamide and AA in CRPC has been associated with AR copy number gain, 
somatic point mutations and the expression of alternatively spliced AR (5-8).  Truncated AR-V7 
expression in circulating tumor cells (CTC), and CRPC biopsies has been linked to resistance to 
AA and enzalutamide highlighting an urgent need for alternative treatment strategies in CRPC 
effectively targeting both persistent AR-FL and AR splice variant signaling.  
Onalespib is a synthetic, non-ansamycin, small molecule inhibitor of Heat Shock Protein 90 
(HSP90) (Kd 0.71 nM) identified by fragment screening and subsequent structure-based drug 
design  (9-12). HSP90 is required for the functional stabilization of numerous client proteins 
involved in cell growth and differentiation, including the full-length AR (AR-FL)(13, 14). 
Inhibition of  HSP90 by onalespib results in proteasomal degradation of client proteins (12, 15) 
and inhibition of multiple signal transduction pathways, including the AR-FL signaling in both 
hormone-sensitive and CRPC models (15, 16).  
We have previously shown that onalespib can inhibit growth of a range of tumor cell types, 
including the  CRPC cell line 22Rv1, expressing the AR-V7, and VCaP cell line overexpressing 
the AR-FL (16). HSP90 inhibition effectively depletes both wild-type and promiscuous mutant 
AR-FL. In addition, HSP90 inhibition leads to the depletion of AR-V7 splice variant protein by 
downregulating AR-V7 mRNA splicing.  
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Modulation of HSP90, a ubiquitously expressed and highly abundant molecular chaperone, is an 
attractive therapeutic strategy in CRPC, as it offers the prospect of simultaneously inhibiting the 
following: (1) Multiple kinase-dependent signaling pathways that control cell growth, resistance 
to apoptosis, and post-translational modification of AR, including AKT and RAF; (2) The 
expression of both AR-FL and AR-V7 splice variant; 3) The expression of GR, which has also 
been implicated in CRPC(17).  Various preclinical studies support this hypothesis  (16, 18-21). 
Moreover, durable antitumor activity was shown in a patient suffering from CRPC in a Phase 1 
study of the geldanamycin derivative alvespimycin (17-DMAG) (22), although tanespimycin 
(17-AAG) was not active (23). Since HSP90 inhibition offers the prospect to block both AR-FL 
signaling and AR splicing we hypothesized that AA/P in combination with onalespib would have 
antitumor activity in patients progressing on AA/P by overcoming multiple potential 
mechanisms of resistance to AA/P. We therefore conducted a Phase 1/2 study to evaluate the 
tolerability and the antitumor and pharmacodynamic activity of onalespib in combination with 
AA/Pin subjects with CRPC progressing on AA/P.   
Subjects, Materials, and Methods  
Study Centers and Subject Population 
A total of 33 study centers (21 in the US, 10 in the UK, 1 in Canada, and 1 in Spain) participated 
in the study.  
Inclusion criteria included histologically or cytologically confirmed adenocarcinoma of the 
prostate without neuroendocrine differentiation or small cell histology; prior castration by 
orchiectomy and/or luteinizing hormone-releasing hormone agonist with or without antiandrogen 
and documented serum testosterone <50 ng/dL; Eastern Cooperative Oncology Group 
Performance Status (ECOG PS) ≤2; no AR antagonist treatment within 6 weeks prior to first 
dose of study drug; receiving AA/P therapy for ≥1 month; documented disease progression on 
AA/P defined by one or more of the following: (1) prostate-specific antigen (PSA) progression 
according to PCWG2 criteria with 3 consecutive rising PSA measurements, all collected at least 
1 week apart (24), (2) radiographic progression in soft tissue or bone by  revised Response 
Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) (25) for subjects with measurable 
disease, or (3) bone disease progression defined by 2 or more new lesions on 2 consecutive bone 
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scans in the absence of falling PSA; CTC count ≥1 detected at screening (Part A only); adequate 
bone marrow function; adequate hepatic function; adequate renal function; willing to provide 
pre-existing diagnostic or resected tumor samples. Complete list of Inclusion and Exclusion 
Criteria is provided in Supplementary Methods. 
Exclusion criteria included prior anti-cancer treatment with any Heat Shock Protein 90 (HSP90) 
inhibitor; screening QTc >450 msec; known symptomatic brain or central nervous system 
involvement such as a result of cord compression; contraindication to corticosteroids use or 
history of pituitary or adrenal dysfunction; prior dose reduction of abiraterone acetate as a result 
of increased transaminases. Standard washout period from previous chemotherapy or 
radiotherapy treatment was required. The study was conducted in accordance with Good Clinical 
Practice guidelines, in compliance with local and/or national regulations, and in accordance with 
the ethical principles that have their origin in the Declaration of Helsinki. All patients gave 
written informed consent, and approval was obtained from the Institutional Review committees 
at each participating institution. The study is registered on ClinicalTrials.gov (NCT01685268). 
Study schema and CONSORT diagram is provided in Supplementary Materials. 
Study Design and Dosing Regimens 
This study was designed as a 2-part, Phase 1/2, open-label, parallel-group, randomized trial in 
subjects with CRPC progressing on AA/P 
Part A consisted of an assessment of the following using the combination of onalespib with 
AA/P in two different regimens: safety and tolerability, pharmacokinetics, antitumor activity, 
pharmacodynamics in fresh tumor biopsies and circulating tumor cells including and AR 
depletion. Subjects were randomized to receive one of two different treatment regimens of 
onalespib in combination with AA 1000 mg by mouth (PO) daily (QD) and prednisone or 
prednisolone 5 mg PO twice daily (BID), as follows: 
 Regimen 1 (once weekly): onalespib given as a 1-hr intravenous (IV) infusion at a 
starting dose of 220 mg/m
2
 once weekly for 3 weeks in a 4-week cycle. 
 Regimen 2 (twice weekly): onalespib administered as a 1-hr IV infusion at starting dose 
of 120 mg/m
2
 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle. 
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Dose-limiting toxicity (DLT) was defined as (1) Grade 4 neutropenia or thrombocytopenia 
persisting for more than 1 week or was associated with neutropenic fever or bleeding, or (2) 
Grade 3 or 4 non-hematologic toxicity. The DLT window encompassed the first 28 days of 
treatment.  
The maximum tolerated dose (MTD) was defined as the highest dose with ≤1 DLT in 6 subjects 
and was confirmed by enrollment of an additional ≥14 subjects. These additional subjects were 
randomized to one of the two regimens at the identified MTD. The absence of at least 1 response 
in 14 evaluable subjects in either of the treatment arms was to indicate antitumor activity in that 
arm of <20% with 95% confidence; that arm was not to proceed to Part B. A data review 
committee was to select the best treatment regimen and dose of onalespib in combination with 
AA/P to continue evaluation in Part B, the selection was to be based on combined assessment of 
safety, antitumor activity, and biological activity. 
In Part B of the trial, subjects were to be randomized to the selected treatment regimen and dose 
of onalespib in combination with AA/Pfrom Part A, or to onalespib alone. Treatment with 
onalespib alone was to be administered at the monotherapy MTD using the same treatment 
regimen that was selected for use in the combination treatment arm. However, due to the absence 
of meaningful antitumor activity and minimal evidence of client protein knockdown at the MTD 
for both regimens in Part A, Part B of the study was not performed.  
Treatment assignments for individual subjects were determined through a computer-generated 
randomization list prepared by Medpace (Cincinnati, OH) and accessed by using an interactive 
voice response system.  
Efficacy Assessment  
Response rate was based on one or more of the following:  
 Complete response (CR) or partial response (PR) with 30% decrease in change of sum of 
longest diameters of target lesions, according to RECIST 1.1 (25) 
 PSA response defined as ≥50% decrease in PSA at 12 weeks according to PCWG2 
criteria (24) in the absence of disease progression 
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 Conversion of CTC count, defined as decline in CTC count from ≥5 cells/7.5 mL of 
blood to <5 cells/7.5 mL of blood, or a 30% decrease in CTC count from baseline at 
Week 12 in the absence of disease progression.  
Blood samples for CTC enumeration were collected at screening, pre-dose Day 1 and 48-72 
hours after Day 15 in Cycle 1, pre-dose Day 1 of each cycle up to Cycle 4, and every 8 weeks 
post Cycle 4. Blood samples for CTC characterization were collected at screening, pre-dose Day 
1 and 48-72 hours after Day 15 in Cycle 1. CTCs were enumerated using the CellSearch® 
System (San Diego, CA). 
Pharmacodynamics  
Minimally invasive tumor biopsies (bone biopsies, soft tissue biopsy, or any other tissue that 
could be safely biopsied) were performed at Screening and 48-72 hours after Day 15 of Cycle 1 
to assess for client protein depletion due to onalespib. Protein levels in formalin-fixed and 
paraffin embedded (FFPE) tissue were determined by immunohistochemistry (IHC) 
(Supplementary Methods). Nuclear and cytoplasmic staining intensity were semi-quantitatively 
assessed using the H-score formula: 3 x percentage of strongly staining nuclei + 2 x percentage 
of moderately staining nuclei + percentage of weakly staining nuclei, giving a range of 0 to 300 
(26). Evaluation of all IHC sections was done by a pathologist blinded to the subjects' clinical 
characteristics and treatment data. Analysis was performed if at least 50 cancer cells were 
identified in the section. Ki67 results were recorded as the percentage of immunoreactive cells. 
Levels of AR, a relevant client in prostate cancer, were also evaluated in CTCs using an 
immunofluorescent assay on the CellSearch System (27).  
Pharmacokinetics 
Blood samples for assessment of abiraterone plasma concentrations were taken over an 8-hr 
period at screening at the following timepoints:  pre-dose, 0.5 (±5 min), 1 (±5 min), 2 (±5 min), 3 
(±5 min), 4 (±5 min), 6 (±10 min), and 8 hours (±1 hr) following AA/P administration. Blood 
samples for assessment of onalespib plasma concentrations were taken over an 8-hr period 
beginning on Cycle 1, Day 1 (C1D1)(Regimen 1) or on C1D2 (Regimen 2) at the following 
timepoints: pre-dose, 0.5 (±5 min), 1 (to coincide with the end of AT13387 infusion ±5 min), 2 
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(±5 min), 3 (±5 min), 4 (±5 min), 6 (±10 min), and 8 hours (±1 hr) from the start of infusion of 
onalespib. .. The pharmacokinetic profiles of abiraterone and onalespib were characterized by 
analysis of Lithium heparin-treated plasma by validated liquid chromatography-mass 
spectrometry/mass spectrometry methods, with a dynamic assay range of 0.5 - 500 ng/mL for 
abiraterone and of 1.0- 1000 ng/mL for onalespib. Pharmacokinetic non-compartmental analysis 
and statistical analyses were performed using Pharsight® Knowledgebase ServerTM (PKS) 
version 4.0.2 and WinNonlin® 5.3 
 
Safety Assessments 
Safety was assessed by subject-reported and investigator-observed AEs, along with concomitant 
medications, physical examination, clinical laboratory tests, vital signs, ECOG performance 
status, ECGs, and ECHO/MUGA scans. All AEs were graded according to the NCI CTCAE, 
v4.1. Visual symptoms were assessed by use of a Visual Assessment Questionnaire.  In Part A 
ECGs were performed in triplicate at screening, before and at the end of infusion (+1 hr) on all 
treatment days for Regimens 1 and 2 in Cycle 1, then before treatment on all treatment days in 
subsequent cycles. Fridericia's formula was used to calculate the QTc interval throughout the 
study. Central ECG monitoring was used in Part A 
Statistical Methods 
The estimated response rate and 95% confidence intervals (CIs) were computed for each regimen 
using the Clopper-Pearson exact CI, if appropriate. The Fisher’s exact test was also used to 
compare response rates for the two regimens. A p value of ≤0.10 was taken as evidence of a 
difference. The 95% CI for the difference between proportions was also computed using the 
normal approximation, if appropriate. PSA response rate, response rate per RECIST 1.1, and 
CTC count conversion rate were analyzed in a similar manner. PFS was defined the number of 
days from the day the subject received study medication to the date of disease progression or 
death.  Progression was defined according to PCWG2  criteria (24). Progression-free survival for 
subjects who withdraw from the study without documented progressive disease (PD) by PCWG2 
criteria were censored on the day of study withdrawal. PFS and overall survival (OS) were 
evaluated using the Kaplan-Meier estimate and summaries of the number and percentage of 
subjects with an event. Median time to progression, median time to death, and 95% CIs were 
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determined. Comparison of Regimen 1 and Regimen 2 was made by log-rank test. Subjects were 
included in the pharmacodynamic analyses if they had provided sufficient samples (i.e. pre- and 
post-treatment biopsy samples) for the pharmacodynamic tests. T-tests were used to compare 
continuous variables. All tests were two sided and a p-value of 0.05 or less was considered 
statistically significant. 
Results 
Patient demographics. A total of 49 subjects were randomized and 48 were treated in the dose-
finding stage of the study (n = 23 in Regimen 1, and n =25 in Regimen 2). Median age was 68 
years (range, 55-90 years). Demographics and baseline characteristics of subjects are provided in 
Table 1.  
Dose Escalation and MTD. All subjects in each regimen received at least 1 cycle of study 
treatment at the starting dose. In Regimen 1, 3/23 subjects were dose-escalated from 220 mg/m
2
 
to 260 mg/m
2
, and these 3 each received 1 cycle of study treatment at the higher level. In 
Regimen 2, 3/25 subjects were dose-escalated from 120 mg/m
2
 to 160 mg/m
2
, and 1 subject 
received 4 cycles of study treatment at the higher dose. Four subjects had DLTs in the study (2 in 
Regimen 1 at 260 mg/m
2
; and 2 in Regimen 2 at 160 mg/m
2
). All 4 DLTs were Grade 3 diarrhea, 
persisting despite optimal symptomatic treatment, and all were considered related to onalespib. 
As a result, the doses of 220 mg/m
2
 in Regimen 1 and 120 mg/m
2
 in Regimen 2 were considered 
the protocol-defined MTDs. 
Adverse Events 
All 48 subjects (100%) experienced at least 1 AE, and all 48 subjects experienced at least 
1 treatment-emergent adverse event (TEAE). TEAEs that occurred in at least 10% of subjects 
and that were considered related to onalespib are shown in descending order in Table 2. Overall, 
related TEAEs with highest incidence were diarrhea (94%, with 21% Grade 3), fatigue (63%, 
with 13% Grade 3), decreased appetite (52%; none were Grade 3), and nausea (50%; with 2% 
Grade 3). No shifts ≥2 CTCAE Grades in QTc from baseline were observed in the study. Three 
related TEAE were reported as Grade 4 (increased amylase in Regimen 1; thrombocytopenia and 
increased amylase in Regimen 2).  
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Fifteen subjects (31.3%) experienced SAEs during the study; 2 subjects (4.2%) died on study as 
a result of an SAE, but the SAEs were considered not related to study treatment. Seven other 
subjects (14.6%) had an SAE considered related to study treatment; these were Grade 3 diarrhea 
(n=4), Grade 3 dehydration (n=1), and Grade 2 left chest pain (n=1). 
Pharmacodynamics 
The pharmacodynamic signature for HSP90 inhibition has been established and used in previous 
clinical trials (22, 28, 29). This signature includes depletion of client proteins such as CDK4, and 
CRAF, and elevation of certain heat shock proteins (eg, HSP72, the inducible isoform of HSP70) 
(22, 28, 30). In the current study CTCs and tumor biopsies were collected to examine 
pharmacodynamic biomarkers to pursue the Pharmacological Audit Trail (PhAT) (31, 32). 
HSP90 target engagement was evaluated by measuring the degree of depletion of protein clients 
relevant to prostate cancer (AR, GR) and the induction of HSP72 protein in paired pre- and post-
treatment tumor tissue biopsies. Achievement of biological activity was evaluated by measuring 
the proliferation biomarker Ki67 and the apoptotic biomarker cleaved caspase 3. Levels of AR 
were also evaluated in CTCs using an immunofluorescence assay on the CellSearch System (27).  
Paired tumor tissue biopsies were collected from 7 subjects. One of the matched biopsies 
contained <50 cancer cells, resulting in a total of 6 paired pre- and post- dose biopsies available 
for comparison (as described in 34). AR protein expression was evaluated using an antibody 
against the N-terminus domain (AR-NTD) binding the AR-FL and AR variants; and an antibody 
directed against the C-terminus (AR-CTD), specific for the AR-FL. The AR-NTD was highly 
expressed in CRPC biopsies taken before starting onalespib treatment both in the nucleus and in 
the cytoplasm. Comparison of paired biopsies obtained pre- (Screening) and post-dose (Cycle 1 
Day 17) demonstrated a reduction in nuclear AR-NTD in 5/6 patients (Figure 1A) (paired t-test 
p= 0.01). AR-CTD was also reduced in 3/6 patients (Figure 1B). Cytoplasmic GR was also 
depleted following onalespib treatment (paired t-test p= 0.003) (Figure 1C). HSP72 was 
significantly up-regulated following onalespib treatment in keeping with HSP90 inhibition 
(paired t-test p= 0.005) (Figure 1D). Changes in tumor cell proliferation following onalespib 
treatment were evaluated by measuring the proliferation marker Ki67 in paired tumor tissue 
biopsies. Overall no significant changes were observed (data not shown). Increases in apoptosis 
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following onalespib treatment were evaluated by measuring the apoptotic biomarker cleaved 
caspase 3. Overall no significant changes were observed (data not shown). Representative 
images of IHC staining are shown for one subject in Figure 1E. 
Thirty-two patients had samples collected before starting treatment (at screening and/or C1D1 
pre-dose) and on C1D17. Sixteen subjects had at least 5 CTCs/7.5 mL in the baseline sample, 
and AR results available at baseline and on-treatment and were included in the analysis. Three of 
7 subjects (42%) that received weekly onalespib (Regimen 1) had a decline in proportion of AR 
positive CTCs >30% on-treatment. Four of 9 subjects (44%) that received twice-weekly 
onalespib had a >30% decline on-treatment (C1D17) (Figure 2). 
Pharmacokinetics  
PK evaluations were performed on plasma samples obtained from 44 subjects (n=20 for 
onalespib 120 mg/m
2
/dose [Regimen 2], n=2 for 160 mg/m
2
/dose [Regimen 2], n=18 for 
220 mg/m
2
/dose [Regimen 1], and n=3 for 260 mg/m
2
/dose [Regimen 1]). Onalespib showed a 
biphasic decline with a two-compartmental disposition. Onalespib exposures increased in a dose-
proportional manner and were similar to those observed in the single agent Phase 1 dose 
escalation study (29), suggesting no PK interaction. The PK profile of onalespib appeared 
reproducible and similar between Regimens 1 and 2, with moderate inter-individual variability 
across all dose levels in each regimen. Onalespib mean AUC0-t and Cmax estimates ranged from 
1480 to 3550 ng*hr/mL, and from 636 to 1850 ng/mL, respectively. 
The exposures of abiraterone generally decreased when abiraterone was administered in 
combination with onalespib, although due to PK variability of AA the significance of these 
findings are uncertain since no direct metabolic drug-drug interactions was expected, although 
this could be due to reduced gastrointestinal transit time as a result of onalespib AEs (diarrhea) 
observed on onalespib dosing days.  
Efficacy  
Overall, no subjects in either regimen showed an objective tumor response according to RECIST 
v1.1, and likewise no subjects in either regimen showed a response in PSA (ie, no response in 
PSA ≥50% decrease at Week 12 per PCWG2). Eight subjects (35%) in Regimen 1 and 7 subjects 
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(28%) in Regimen 2 had a conversion of CTCs from ≥5 cells/7.5 mL of blood to <5 cells/7.5 mL 
or a decrease of more than 30% from the baseline CTC value on-treatment (Figure 3). However, 
these declines were transient, and CTC values increased rapidly after treatment. Maximum 
percentage changes in PSA and CTCs by regimens are shown in Figure 3A and 3B, respectively. 
The median PFS in Regimen 1 (n=23) was 77 days (95% CI: (71.0, 83.0)) and in Regimen 2 
(n=24) was 84 days (95% CI: (77.0, 158.0). PFS was not different between the regimens 
(p>0.23). The median OS in Regimen 1 (n=23) was 10.6 months (95% CI: (3.8, NA)) and in 
Regimen 2 (n=24) was 8.9 months (95% CI: 4.8, NA)). Median OS was not different between 
the regimens (p=0.52). 
DISCUSSION 
Despite the promise of HSP90 inhibitors as a class of therapeutic agents, these agents have, to 
date, shown variable results in clinical trials. Encouraging single-agent activity has been seen in 
specific molecular backgrounds, e.g., HER2 amplification in breast cancer and EGFR mutations 
and ALK rearrangements in NSCLC, suggesting that client protein sensitivity to HSP90 
inhibition is likely to be a key contributor to HSP90 inhibitor success (13).  In other cancer types 
HSP90 inhibition has been disappointing, despite the fact that the oncogenic constituents of such 
cancers are among HSP90's clientele. In general, to date, single-agent activity of HSP90 
inhibitors has not been adequate to justify market approval. Few combination trials of HSP90 
inhibitors have been conducted. 
This study represents the first clinical trial of an HSP90 inhibitor in combination with AA/P in 
patients with metastatic CRPC. HSP90 treatment results in depletion of AR-FL and AR-V7, as 
well as GR, in preclinical models, hence treatment with an HSP90 inhibitor such as onalespib 
was hypothesized to address resistance to agents such as AA or enzalutamide that act via the 
AR-FL (27). Resistance to these agents may be mediated by AR alterations, including the 
expression of AR-V7 splice variant (5, 6). This study documented progression on AA/P 
treatment as a condition for study entry and explored the ability of HSP90 inhibition to overcome 
resistance to AA/P.  
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The combination of the HSP90 inhibitor with AA appeared to be tolerated at onalespib doses 
below the single-agent MTD  (220 mg/m
2
 weekly vs 260 mg/m
2
 for the single agent weekly 
regimen (10, 29); 120 mg/m
2
 vs 160 mg/m
2
 for the twice weekly on two consecutive day 
regimen (11) with gastrointestinal toxicity in this population, most notably diarrhea being dose 
limiting. AA/P has a 5% reported incidence of diarrhea, but despite the reported single-agent 
MTDs, many subjects were unable to complete three full dosing cycles due to either AEs, study 
withdrawal, or disease progression. This may reflect additive toxicity, and perhaps the study of a 
more elderly population than studied in onalespib Phase 1 trials, or both. 
Pharmacodynamic studies in tumor biopsies collected 24-48 hours post-dose, although limited in 
numbers, demonstrated a significant induction of HSP72; this was, however, accompanied by 
only a modest depletion of AR and GR and no changes in tumor proliferation or apoptosis. CTC 
studies also demonstrated a transient decline in AR-positive CTCs in some patients. This lack of 
clinical activity accompanied by lack of sustained HSP90 client protein depletion did not justify 
the further evaluation of onalespib in combination with AA/P at the doses and schedule we 
evaluated. One possible explanation for the lack of activity in our trial is that the tolerable 
regimens did not achieve a sustained and durable effect on AR. However, the need for IV 
infusions and the toxicity reported prevented us from exploring more aggressive onalespib 
dosing schedules. Preclinical studies, both in vitro and in vivo, have shown that onalespib causes 
prolonged depletion of client proteins in tumor xenografts (33), but this may not be the case in 
mCRPC patients. In this study we were unable to demonstrate more than modest depletion of 
client protein 48 hours after treatment administration.  
Induction of HSP72 has been widely used as a biomarker to monitor the pharmacodynamic 
impact of HSP90 inhibitors. However, increasing evidence suggests that HSP72 induction, while 
necessary, is not itself sufficient to predict response to these agents. For example, in clinical 
trials of 17-DMAG, HSP72 levels measured in PBMCs showed no correlation with clinical 
response (35,36). Direct evaluation of the client and modulation of the pathway(s) of interest 
coupled with the evaluation of downstream biological effects (eg, increase in apoptosis, 
reduction in proliferation), as performed in this study, are critical for evaluation of antitumor 
effects and to optimally develop HSP90 inhibitor therapy.  
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Preclinical studies have revealed a number of mechanisms whereby cancer cells can be rendered 
less susceptible to the effects of HSP90 inhibition. Firstly, HSP90 inhibition elicits both the 
depletion of client proteins and the activation of a heat shock response mediated by HSF1. As a 
result of HSF1 activation, expression of inducible HSPs (e.g. HSP72, HSP27) is dramatically 
upregulated, and is often used as a readout of HSP90 target engagement. However, these pro-
survival chaperones may limit the anti-tumour activity of HSP90 inhibitors and may play a role 
in resistance to HSP90 inhibition, rescuing client proteins including AR and its splice variants 
from degradation. Inhibition of HSF1, HSP70 or HSP27 has been reported to increase cell 
sensitivity to HSP90 inhibition and induction of apoptosis and may be key to more robust AR 
blockade (37-40).  
In this study, we observed induction of HSP72, confirming target engagement, and some 
depletion of AR and GR post-onalespib treatment, but evidence of residual nuclear AR coupled 
with no changes in Ki67 or cleaved caspase 3 suggested that the degree of HSP90 inhibition was 
not sufficient to translate into an effective blockade of AR signaling pathway and a reduction in 
cancer cell proliferation and increased apoptosis. In summary, for both the weekly or twice 
weekly regimens of onalespib in combination with AA/P, there was mild evidence of some 
biological effect, however this effect did not translate into clinical activity, hence further 
exploration of this combination is not justified. 
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Table 1. Demographics and Baseline Characteristics 
Demographic Characteristics 
Regimen 1  
(N=23) 
Regimen 2  
(N=25) 
Total 
(N=48) 
Age (yr) n 23 (100%)  25 (100%)  48 (100%) 
 Mean 71.3  68.0  69.5 
       
       
 Min. 57  55  55 
 Max. 90  84  90 
ECOG PS (n, %) n 23 (100)  25 (100)  48 (100) 
 0 7 (30)  12 (48)  19 (40) 
 1 14 (61)  12 (48)  26 (54) 
 2 2 (9)  1 (4)  3 (6) 
 3 0   0   0  
Prior Chemotherapy/ 
Immunotherapy 
n (%) 18 (78)  20 (80)  38 (79) 
Prior Cancer Surgery n (%) 8 (35)  11 (44)  19 (40) 
Prior Hormone Therapya n (%) 23 (100)  24 (96)  47 (98) 
Prior Radiation Therapy n (%) 18 (78)  17 (68)  35 (73) 
Baseline Gleason Score n 20  23  43 
 <7 2 (9)  2 (8)  4 (8) 
 =7 6 (26)  3 (12)  9 (19) 
 >7 12 (52)  18 (72)  30 (63) 
a  Does not include abiraterone.  
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Table 2. Treatment-Emergent Adverse Events Considered Related to Onalespib (≥10% of Total Subjects) 
  Regimen 1 
(n, %) 
Regimen 2 
(n, %) 
Adverse Event 
Preferred Term
 
Overall Total 
N=48 
220 mg/m
2
 
n=20 
260 mg/m
2
 
n=3 
120 mg/m
2
 
n=22 
160 mg/m
2
 
n=3 
 All Grade 
3,4 
All Grade 
3-, 4 
All Grade 
3, 4 
All Grade 3, 
4 
All Grade 
3- 4 
Diarrhea 45 (94) 10 (21) 19 (95) 3 (15) 2 (67) 2 (67) 21 (96) 3 (14) 3 (100) 2 (67) 
Fatigue 30 (63) 6 (13) 15 (75) 1 (5) 0 0 14 (64) 5 (23) 1 (33) 0 
Decreased 
Appetite 
25 (52) 0 10 (50) 0 1 (33) 0 11 (50) 0 3 (100) 0 
Nausea 24 (50) 1 (2) 9 (45) 0 1 (33) 0 13 (59) 1 (5) 1 (33) 1 (4) 
Vomiting 15 (31) 0 5 (25) 0 0 0 10 (46) 0 0 0 
Dry Mouth 10 (21) 0 5 (25) 0 0 0 4 (18) 0 1 (33) 0 
Dizziness 8 (17) 0 3 (15) 0 0 0 5 (23) 0 0 0 
Infusion Site 
Pain 
7 (15) 0 4 (20) 0 0 0 2 (9) 0 1 (33) 0 
Anemia 7 (15) 5 (10) 3 (15) 1 (5) 0 0 4 (18) 4 (18) 0 0 
Headache 6 (13) 0 3 (15) 0 0 0 3 (14) 0 0 0 
Weight 
Decreased 
6 (13) 0 2 (10) 0 0 0 3 (14) 0 1 (33) 0 
Dysgeusia 6 (13) 0 3 (15) 0 0 0 3 (14) 0 0 0 
Dry Eye 5 (10) 0 2 (10) 0 0 0 3 (14) 0 0 0 
Photopsia 5 (10) 1 (2) 2 (10) 0 0 0 3 (14) 1 (5) 0 0 
Insomnia 5 (10) 0 2 (10) 0 0 0 3 (14) 0 0 0 
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Figure Legends 
 
Figure 1. Changes in (A) nuclear AR-NTD, (B) nuclear AR-CTD, (C) GR and (D) HSP72 expression in paired fresh tumor tissue 
biopsies obtained pre- and post- onalespib treatment. Immunostaining was assessed using an H-score, calculated by multiplying each 
intensity level (0, for absent, 1 for weak, 2 for moderate, and 3 for intense stain) by the corresponding percentage of positive cancer 
cells; (E) Representative images of AR, GR, Ki67 and HSP72 immunohistochemistry staining in paired fresh tumor tissue biopsies 
(lymph node biopsy) taken pre-dose Cycle 1 Day 1 and 48 hours post-dose on Cycle 1 Day 17. Micrographs show AR-NTD, HSP72, 
Ki67, and GR expression by DAB immunohistochemistry method.  
Figure 2. (A) Waterfall plot showing maximal changes in the percentage of AR positive CTCs in individual subject with ≥5 CTCs/7.5 
mL at baseline. Cycle 1 Day 17 sample was compared with Cycle 1 Day 1. When Cycle 1 Day 1 sample was not available, post-dose 
sample was compared with the screening sample. (B) Representative images of AR expression in individual CTCs from two patients 
at screening, Cycle 1 Day 1 and Cycle 1 Day 7. CTCs were isolated and detected on the CellSearch platform. The enriched cells were 
stained by immunofluorescence using antibodies specific for Cytokeratin (keratin 8, 18 and 19) conjugated to Phycoerythrin (CK-PE), 
anti-CD45 conjugated to Allophycocyanin (CD45-APC), the nucleic acid dye 4′,6-diamidino-2-phenylindole (DAPI) and an 
AlexaFluor 488-conjugated rabbit monoclonal antibody directed against the amino-terminus domain of the AR as previously 
described (27) . 
Figure 3. (A) Waterfall plot showing changes in total number of circulating tumor cells by subject. Increases were capped at 100%; 
(B) Maximum percentage change in prostate specific antigen by subject. Increases were capped at 100%.  
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